US Patent 8,658,198: Claim Scope, Expiration, Orange Book Relevance, and Opioid Patent Landscape
US Patent 8,658,198 protects a specific abuse-deterrent transmucosal tablet architecture combining opioid microparticles with larger carrier particles containing an opioid antagonist. The strongest coverage is directed to buprenorphine- or fentanyl-class analgesics paired with naloxone or another listed antagonist, where the active ingredients are delivered through the sublingual or buccal mucosa.
The patent does not broadly cover every buprenorphine/naloxone product. A potentially infringing product must satisfy the full combination of limitations in an asserted claim, including the particle arrangement, carrier-particle composition, transmucosal delivery route, and opioid-antagonist pairing.
What does US Patent 8,658,198 protect?
The patent protects particulate transmucosal pharmaceutical compositions formulated as tablets. Its central technical concept is the association of smaller opioid-analgesic particles with larger carrier particles that contain an opioid antagonist.
The independent composition claim requires:
| Limitation |
Required scope |
| Dosage form |
Tablet |
| Administration |
Sublingual or buccal |
| Active analgesic |
Fentanyl, alfentanil, sufentanil, remifentanil, or buprenorphine |
| Antagonist |
Nalmefene, methylnaltrexone, naltrexone, or naloxone |
| Particle structure |
Analgesic particles attached to, adhered to, or associated with larger carrier-particle surfaces |
| Delivery |
Both opioid analgesic and antagonist delivered transmucosally |
| Carrier excipient |
Carbohydrate, inorganic salt, polymer, or mixture |
The claim is structurally narrower than a conventional composition claim covering only buprenorphine and naloxone. It requires a defined relationship between the opioid particles and the antagonist-containing carrier particles.
What is the commercial significance of the particle architecture?
The architecture is directed to several formulation objectives:
- rapid sublingual or buccal dispersion;
- intimate co-delivery of opioid and antagonist;
- local mucosal exposure;
- reduced suitability for abuse by injection;
- use of larger carrier particles to support adhesion, dispersion, or dose uniformity;
- incorporation of disintegrants and mucoadhesive materials.
The specification’s formulation concept is particularly relevant to opioid-dependence products containing buprenorphine and naloxone. However, infringement depends on the physical structure of the accused product, not merely on the presence of those two active ingredients.
How broad is independent claim 1?
Claim 1 is a combination claim with multiple narrowing elements. Its breadth comes from the alternative lists for the analgesic, antagonist, and carrier excipient. Its principal limitation is the particle association requirement.
A product could avoid claim 1 by omitting or failing to establish any of the following:
- a tablet dosage form;
- sublingual or buccal administration;
- one of the five listed opioid analgesics;
- one of the four listed opioid antagonists;
- carrier particles larger than the analgesic particles;
- association of the analgesic particles with carrier-particle surfaces;
- transmucosal delivery of both active ingredients;
- a qualifying carbohydrate, inorganic salt, polymer, or combination in the carrier particles.
A product containing buprenorphine and naloxone in a sublingual tablet is not automatically within the claim. The claim requires the specific particulate arrangement.
Does the claim require the antagonist to be on the carrier particles?
Claim 1 states that the opioid analgesic particles are attached to, adhered to, or associated with carrier particles comprising the opioid antagonist. The claim therefore requires the carrier particles to contain the antagonist. The analgesic is not required to be chemically bonded to the carrier.
The terms "attached to," "adhered to," and "associated with" create alternative forms of physical association. The claim does not require a particular manufacturing process, coating mechanism, or bonding chemistry.
The phrase "larger in size" is also material. The carrier particles must be larger than the opioid-analgesic particles. Claims 11 and 12 provide specific carrier-particle size ranges of approximately 50 to 1,000 micrometers and 100 to 800 micrometers, respectively.
What do dependent claims 2 through 26 add?
The dependent claims build a detailed formulation position around the broad composition claim.
Excipient and carrier-particle limitations
Claims 2 and 3 identify preferred carrier materials:
- sugar;
- mannitol;
- lactose;
- sodium chloride;
- calcium phosphate;
- dicalcium phosphate hydrate or dihydrate;
- tricalcium phosphate;
- calcium carbonate;
- barium sulfate;
- microcrystalline cellulose;
- cellulose;
- crosslinked polyvinylpyrrolidone.
Claim 3 narrows the formulation to mannitol, cellulose, microcrystalline cellulose, crosslinked polyvinylpyrrolidone, or mixtures of those materials.
Mannitol and microcrystalline cellulose are commercially important because both are common tablet excipients and can support particle flow, compaction, mouthfeel, and rapid disintegration.
Particle-size limitations
Claims 4 and 5 require the opioid analgesic to be in microparticle form, with a weight-based mean diameter below approximately 15 micrometers.
This is a substantial limitation for enforcement. Particle size may be established through:
- laser diffraction;
- sieve analysis;
- microscopy;
- manufacturing records;
- batch specifications;
- process-development reports.
A product may contain micronized buprenorphine or fentanyl without necessarily satisfying the claim if the particles are not associated with larger antagonist-containing carrier particles.
Dose and concentration limitations
Claims 6 and 7 specify opioid-analgesic concentrations of:
- approximately 0.0005% to 20% by weight; or
- approximately 1% to 7% by weight.
Claims 8 and 9 specify a unit dose of approximately:
- 1 microgram to 20 milligrams; or
- 5 micrograms to 15 milligrams.
These ranges cover a wide range of opioid doses. The dose limitations may be useful in enforcement against products with different formulation architectures but similar active-ingredient quantities.
Naloxone limitation
Claim 10 narrows the antagonist to naloxone. This is likely the most commercially significant dependent claim because buprenorphine/naloxone products are the principal commercial products implicated by the claim set.
A buprenorphine/naloxone tablet could fall within claim 10 if it also satisfies the carrier-particle and particle-size limitations.
Mucoadhesive limitations
Claims 13 through 20 add a bioadhesion or mucoadhesion-promoting agent, at least partly presented on the carrier-particle surfaces.
The claimed materials include:
- cellulose derivatives;
- starch derivatives;
- acrylic polymers;
- polyvinylpyrrolidone;
- polyethylene oxide;
- chitosan;
- gelatin;
- sodium alginate;
- pectin;
- xanthan gum;
- guar gum;
- carbomers;
- crosscarmellose sodium.
Claims 17 through 19 focus on crosscarmellose sodium and crosslinked polyvinylpyrrolidone, with a claimed concentration of approximately 0.1% to 25%, or 1% to 15%, by weight.
Claim 20 specifies a mucoadhesive-particle size of approximately 1 to 100 micrometers.
These claims create narrower positions that may be relevant where the accused product’s formulation records identify a mucoadhesive excipient as a functional component rather than merely a conventional tablet disintegrant.
Disintegrant limitations
Claims 21 through 26 cover disintegrants that accelerate disintegration or dispersion after contact with saliva or mucous membranes.
The listed disintegrants include:
- crosslinked polyvinylpyrrolidone;
- carboxymethyl starch;
- natural starch.
Claim 24 specifies possible locations for the disintegrant:
- between carrier particles;
- attached to or associated with carrier-particle surfaces;
- within carrier particles.
Claim 26 specifies a disintegrant concentration of approximately 2% to 7% by weight.
This portion of the claim set gives the patent a secondary formulation position. A product that avoids the narrower mucoadhesive claims may still require analysis under the disintegrant claims if the same excipient performs both functions.
What do method claims 27 through 33 cover?
Claims 27 through 33 cover use of the composition, rather than the composition alone.
Administration claims
Claim 27 covers sublingual or buccal administration of the composition of claim 1. Claims 28 and 29 address use in opioid-dependent individuals and describe resistance to abuse.
Reversal and overdose claims
Claims 30 through 32 cover administration intended to reverse opioid effects, including euphoria and effects produced by injection of an opioid composition.
Claim 33 covers treatment of narcotic overdose or diagnosis of suspected opioid addiction.
These claims raise enforcement and litigation issues because method claims generally require proof that the claimed administration occurred or that the accused product was specifically directed toward the claimed use. A product claim is usually more significant in a generic-launch dispute because it can be asserted against the manufacture, sale, or importation of the dosage form itself.
When does US Patent 8,658,198 lose exclusivity?
The patent issued on February 25, 2014. Its effective expiration is expected to fall in the mid-2020s based on the underlying priority and US patent-term rules. The precise expiration date depends on the patent family’s earliest effective nonprovisional filing date, patent-term adjustment, terminal disclaimers, and any applicable patent-term extension.
For commercial planning, the relevant points are:
| Event |
Date or status |
| Patent |
US 8,658,198 |
| Grant date |
February 25, 2014 |
| Technology |
Particulate transmucosal opioid-antagonist composition |
| Expected term |
Mid-2020s, subject to USPTO term calculation |
| Product category |
Small-molecule opioid dependence and abuse-deterrent formulations |
| Biosimilar exclusivity |
Not applicable |
| Paragraph IV relevance |
Applicable if listed for an FDA-approved product |
Patent expiration does not itself eliminate other barriers. Continuation patents, formulation patents, method-of-use patents, regulatory exclusivity, controlled-substance requirements, and manufacturing know-how may affect market entry after this patent expires.
What is the Orange Book status of US 8,658,198?
The Orange Book status must be assessed at the approved-product level. A patent appears in the Orange Book only when the NDA holder submits it for an approved drug and FDA accepts the listing under applicable requirements.
The relevant commercial reference products include:
- Suboxone buprenorphine/naloxone sublingual tablets;
- Suboxone buprenorphine/naloxone sublingual film;
- Zubsolv buprenorphine/naloxone sublingual tablets;
- generic buprenorphine/naloxone sublingual tablets and films.
A patent directed to a specific particulate composition may be listed against an NDA if the NDA holder represents that the approved product is covered by at least one claim. Listing does not establish validity or infringement. FDA does not determine whether the patent claims are valid.
For generic applicants, an Orange Book-listed patent can trigger:
- a Paragraph IV certification;
- a 30-month stay if the NDA holder files timely infringement litigation;
- a potential 180-day exclusivity period for the first qualifying Paragraph IV generic applicant;
- delayed approval or launch depending on litigation and settlement terms.
A formulation patent that is not Orange Book-listed can still support infringement litigation in other contexts, but it generally does not create the same Hatch-Waxman approval consequences.
Which companies are most exposed to this patent family?
The primary exposure is among companies selling buprenorphine/naloxone transmucosal products or developing substitutes with similar particulate structures.
| Company or product group |
Relevant exposure |
| Indivior and Suboxone products |
Buprenorphine/naloxone transmucosal products; major Orange Book and litigation relevance |
| Orexo and Zubsolv |
Buprenorphine/naloxone sublingual tablet; competing formulation and patent estate |
| Generic manufacturers |
Potential Paragraph IV and formulation-design risk |
| Film and oral-dissolution developers |
Risk depends on whether the product is a tablet and uses the claimed particle architecture |
| Opioid-antagonist combination developers |
Risk increases where naloxone is incorporated into larger carrier particles |
The patent is less relevant to buprenorphine-only products, methadone products, injectable naloxone, and conventional oral tablets that do not deliver both actives transmucosally.
How does US 8,658,198 compare with competing opioid patents?
Suboxone composition patents
Earlier and related Suboxone patents generally focus on combinations of buprenorphine and naloxone, dosage ratios, treatment of opioid dependence, and pharmaceutical compositions. Those patents can be broader as to formulation architecture but narrower as to specific active ingredients or therapeutic use.
US 8,658,198 is more formulation-specific. It requires:
- particulate opioid delivery;
- larger carrier particles;
- physical association between analgesic and carrier particles;
- transmucosal delivery of both agents.
Sublingual film patents
Sublingual-film patents typically cover:
- polymeric films;
- film layers;
- drug distribution within the film;
- drying and manufacturing methods;
- film dimensions and dissolution characteristics.
A film product may avoid US 8,658,198 because claim 1 requires a tablet. Film patents can still create separate launch barriers even if the particulate tablet patent expires.
Zubsolv-related patents
Zubsolv is a sublingual buprenorphine/naloxone tablet with a distinct formulation and commercial patent estate. Its patents may focus on taste masking, dosage form properties, bioavailability, excipient systems, and manufacturing processes.
The key comparison is structural:
| Issue |
US 8,658,198 |
Typical competing tablet patent |
| Core protection |
Particle-to-carrier association |
Composition, excipient, dissolution, or bioavailability |
| Required antagonist |
One of four listed antagonists |
Often buprenorphine plus naloxone |
| Dosage form |
Tablet |
Tablet or film, depending on patent |
| Delivery route |
Sublingual or buccal |
May be oral, sublingual, or buccal |
| Particle-size limitations |
Central to several claims |
May not be required |
| Abuse-deterrence concept |
Expressly addressed |
May be implicit or absent |
| Design-around potential |
Replace particle architecture or dosage form |
Depends on claim language |
How strong is the patent estate?
The patent has moderate claim breadth and potentially meaningful commercial value, but its enforceability depends heavily on proving formulation structure.
Strengths
- Covers both buprenorphine and fentanyl-class analgesics.
- Includes naloxone and several alternative antagonists.
- Protects a physical particle architecture rather than only a therapeutic indication.
- Includes composition, method-of-use, mucoadhesive, particle-size, dose, and disintegrant claims.
- Targets abuse-deterrent opioid products, a commercially important regulatory and product-design objective.
Weaknesses
- Independent claim 1 contains numerous cumulative limitations.
- The tablet requirement excludes films and many other dosage forms.
- The larger-carrier-particle limitation creates a clear design-around route.
- Particle association and particle-size parameters may be difficult to prove from public product information.
- Method claims require evidence concerning administration and intended use.
- Validity may be challenged on written description, enablement, indefiniteness, anticipation, or obviousness grounds.
- The claim’s broad alternative lists do not eliminate the need to satisfy every structural limitation.
The patent is strongest against a product that intentionally reproduces the disclosed architecture: micronized buprenorphine or fentanyl associated with larger mannitol or cellulose-based particles containing naloxone, combined with a mucoadhesive or swelling disintegrant.
What generic launch scenarios exist?
Scenario 1: Same active ingredients, different architecture
A generic company could use buprenorphine and naloxone in a sublingual tablet but distribute both actives homogeneously through a compressed matrix rather than associating opioid particles with larger antagonist-containing carrier particles. This design would reduce literal infringement risk, although other patents may remain relevant.
Scenario 2: Sublingual film
A film product would likely avoid the tablet limitation of claim 1. The developer would still need to assess film patents, formulation patents, manufacturing patents, and Orange Book-listed claims covering the reference product.
Scenario 3: Different antagonist
Using an antagonist outside the claimed list may avoid claim 1, but the commercial and therapeutic profile would change. Regulatory, clinical, and abuse-deterrence requirements would also need separate analysis.
Scenario 4: Carrier particles outside the claimed ranges
Carrier particles outside the dependent-claim ranges may avoid claims 11 and 12, but claim 1 has no numerical carrier-size range beyond requiring that the carrier particles be larger than the opioid particles.
Scenario 5: Nontransmucosal product
An orally swallowed product would generally avoid the transmucosal limitation, although it would not be a direct substitute for the approved sublingual or buccal reference product without corresponding clinical and regulatory support.
Does the patent create biosimilar risk?
No. US 8,658,198 covers small-molecule opioid formulations. The principal regulatory pathway is the ANDA pathway for generic drugs, not the biosimilar pathway under the Public Health Service Act.
The relevant risks are:
- Paragraph IV certification;
- Hatch-Waxman litigation;
- product-specific patent listings;
- controlled-substance manufacturing and distribution requirements;
- formulation and process patents;
- state and federal opioid-compliance obligations.
What litigation and licensing issues matter?
The most important litigation question is whether US 8,658,198 was listed against a specific NDA and whether the NDA holder asserted it against an ANDA applicant. A patent number alone does not establish that litigation occurred.
Commercial review should distinguish among:
- patent validity challenges;
- infringement litigation;
- Orange Book listing disputes;
- Paragraph IV notices;
- launch-at-risk decisions;
- settlement agreements;
- licenses or covenants not to sue;
- continuation or divisional patents in the same family.
Settlement agreements involving opioid products may include delayed launch dates, authorized generic arrangements, supply provisions, or restrictions on formulation changes. Those terms can materially alter the economic effect of patent expiry.
Key Takeaways
- US 8,658,198 is a formulation patent directed to particulate sublingual or buccal tablets containing an opioid analgesic and opioid antagonist.
- The commercially important embodiment is buprenorphine plus naloxone.
- The core limitation is the association of smaller opioid particles with larger carrier particles containing the antagonist.
- A conventional buprenorphine/naloxone tablet is not automatically within the claims.
- Claims 2 through 26 add excipients, particle sizes, dose ranges, mucoadhesives, and disintegrants.
- Claims 27 through 33 cover administration, abuse resistance, opioid-effect reversal, overdose treatment, and addiction diagnosis.
- The patent issued on February 25, 2014 and is expected to expire in the mid-2020s, subject to the official USPTO term calculation.
- Generic risk depends on Orange Book listing, claim construction, product architecture, and related continuation or competing patents.
- The patent does not create biosimilar risk because the technology concerns small-molecule drug products.
- The clearest design-around strategies are a non-tablet dosage form, a homogeneous matrix formulation, a different particle architecture, or a nontransmucosal route.
FAQs
Can a buprenorphine/naloxone sublingual tablet infringe without using micronized buprenorphine?
Yes. Claims 1 and 10 do not expressly require the opioid analgesic to be a microparticle. Microparticle status is added by claims 4 and 5. A product could potentially implicate the independent claim if its buprenorphine particles are associated with larger naloxone-containing carrier particles.
Does using mannitol automatically create infringement risk?
No. Mannitol is only one listed carrier substance. The product must also satisfy the active-ingredient, tablet, transmucosal, particle-association, and relative-particle-size limitations.
Can a sublingual film infringe claim 1?
Literal infringement of claim 1 would be difficult because the claim requires a tablet. A film could still implicate separate patents covering the same product, active ingredients, manufacturing process, or therapeutic use.
Are the method claims relevant to a generic manufacturer?
Yes, but their practical value may be lower than composition claims. Method-claim enforcement requires proof relating to the product’s intended use, labeling, marketing, or actual administration.
Does patent expiration eliminate all barriers to generic buprenorphine/naloxone entry?
No. Other formulation, process, method-of-use, and product-specific patents may remain. FDA approval, controlled-substance compliance, manufacturing capacity, and settlement agreements can also affect launch timing.
References
- United States Patent and Trademark Office. (2014). U.S. Patent No. 8,658,198, particulate transmucosal pharmaceutical composition claims.
- United States Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- United States Code, 35 U.S.C. §§ 154, 271, 282, 283, 284.
- United States Code, 21 U.S.C. § 355.
- United States Food and Drug Administration. (2024). Abbreviated new drug application submissions and patent certifications.
